TNVax NPs
GBM cells
anti-PD-L1 antibody
anti-CD133 antibody
immune cells
TNVax delivery
TNVax particles
advanced GBM
antigen-antibody interactions
immune suppression
GBM cell lines
proposed TNVax formulation
Induction of immune response
strong immune response
proposed studies
host immune system
tumour specific monoclonal antibody
CD133 antigen
cell activity
Combinatorial Therapeutic Nanovaccine
combinatorial approach
pharmacodynamic studies
novel therapeutic nanovaccine
induction of T
multiple means
multiple modules
antitumour activity
glioblastoma multiforme
strong binding
Site-specific delivery
drug release kinetics
gold nanocage core encapsulating Temozolamide
appropriate murine models
TMZ
cytotoxicity
immunofluorescence
proposal
mauran
characterisation
application
cytokine production
disease
payload
macrophage activation
extremophilic bacterial polysaccharide
histopathological examinations
synthesis
patients
addition
FACS analysis
good immunological memory
conditions
potential outcomes
target site
chemo
Functionalisation
NVax nanoparticles
spectroscopic techniques
evaluations